Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18952842 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHECKPOINT INHIBITOR-RESISTANT TUMORS USING PLINABULIN-BASED COMBINATION THERAPIES | November 2024 | June 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18901530 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | September 2024 | May 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18897889 | ISOXAZOLINE PARASITICIDE FORMULATIONS | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18675317 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | May 2024 | April 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18670556 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | May 2024 | May 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18670524 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | May 2024 | May 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18590435 | BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION | February 2024 | May 2025 | Abandon | 14 | 2 | 0 | Yes | No |
| 18589348 | BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION | February 2024 | June 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18544874 | METHOD TO IDENTIFY AND ALLEVIATE THE SYMPTOMS OF PARKINSONISM/PARKINSON�S DISEASE | December 2023 | December 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18511089 | 9-(2-HYDROXYQUINOLIN-3-YL)-10-(2-HYDROXYETHYL)-3,3,6,6-TETRAMETHYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18325910 | ISOXAZOLINE PARASITICIDE FORMULATIONS | May 2023 | December 2024 | Allow | 18 | 3 | 0 | No | No |
| 18193207 | LASOFOXIFENE TREATMENT OF BREAST CANCER | March 2023 | February 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18116885 | CO-CRYSTALS OR SALTS OF PSILOCYBIN AND METHODS OF TREATMENT THEREWITH | March 2023 | April 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18150955 | NOVEL PYRAZOLE DERIVATIVES | January 2023 | March 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18089567 | A APPLICATION OF CYATHANE DITERPENOIDS IN PREPARATION OF DRUGS FOR TREATING NEUROINFLAMMATION | December 2022 | January 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18080140 | METHODS FOR IMPROVED PROTECTION AND DELIVERY OF AMINOTHIOLS AND ANALOGS THEREOF | December 2022 | June 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18051283 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | October 2022 | April 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17955270 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | September 2022 | April 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17935360 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | September 2022 | July 2024 | Allow | 21 | 2 | 1 | No | No |
| 17935329 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | September 2022 | September 2024 | Allow | 23 | 1 | 1 | No | No |
| 17947858 | SELF-DISINTEGRATING EXCIPIENT COMPOSITION FOR SOLID ORAL DOSAGE FORMS | September 2022 | March 2025 | Abandon | 29 | 3 | 0 | No | No |
| 17895738 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | August 2022 | October 2024 | Allow | 26 | 2 | 0 | No | No |
| 17895849 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | August 2022 | January 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17881306 | Compositions and Methods for the Treatment of Opioid Overdose | August 2022 | January 2025 | Allow | 29 | 4 | 0 | No | No |
| 17811715 | Combination Drugs of Hypoxanthine and Human Immunoglobulin | July 2022 | November 2024 | Allow | 28 | 3 | 0 | No | No |
| 17833836 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | June 2022 | September 2024 | Allow | 27 | 2 | 0 | No | No |
| 17741991 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | May 2022 | July 2024 | Allow | 26 | 2 | 1 | No | No |
| 17736070 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | May 2022 | January 2025 | Allow | 33 | 2 | 1 | No | No |
| 17734745 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | May 2022 | December 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17705746 | USES OF INDOLINONE COMPOUNDS | March 2022 | July 2024 | Allow | 28 | 2 | 0 | No | No |
| 17803164 | OPIOID OVERDOSE REVERSAL MIXTURES | March 2022 | November 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17553434 | AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS | December 2021 | May 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17595655 | NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17507921 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | October 2021 | July 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17600657 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | October 2021 | April 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17489575 | PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE, CHLORTHALIDONE, AND AMILORIDE AND APPLICATION THEREOF | September 2021 | April 2025 | Allow | 43 | 1 | 1 | No | No |
| 17593974 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | September 2021 | May 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17600024 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | September 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17442331 | Amide Compounds, Preparation Method Therefor, and Use Thereof in The Medical Field | September 2021 | June 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17440040 | ACYLAMINOPYRROLO-PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2021 | June 2025 | Allow | 45 | 2 | 1 | No | No |
| 17439548 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17438914 | BULLEYACONITINE D CRYSTAL AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | September 2021 | May 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17434278 | METHODS OF TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA | August 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17423245 | HIV-1 PROTEASE INHIBITORS AND USES THEREOF | July 2021 | July 2025 | Allow | 48 | 2 | 1 | No | No |
| 17372304 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17419129 | A PROCESS FOR PREPARATION OF A STABLE PHARMACEUTICAL COMPOSITION OF BORTEZOMIB | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17419092 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17416119 | SUBSTITUTED QUINOXALINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | June 2021 | January 2025 | Allow | 43 | 2 | 0 | No | No |
| 17416117 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | June 2021 | July 2024 | Allow | 37 | 1 | 0 | No | No |
| 17415985 | PHARMACEUTICAL COMBINATIONS | June 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17415429 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17339414 | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN USING CAPSAICIN | June 2021 | September 2024 | Allow | 39 | 3 | 0 | No | No |
| 17299498 | SELECTIVE PI3Kdelta INHIBITOR AND USE THEREOF | June 2021 | November 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17335929 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17332058 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17296969 | DONEPEZIL EUTECTIC MIXTURE AND USE THEREOF | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17295521 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | May 2021 | August 2024 | Allow | 39 | 1 | 1 | No | No |
| 17292953 | 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17290400 | TREATMENTS FOR ZIKA VIRUS INFECTION | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17289662 | ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF | April 2021 | April 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17289714 | FERROCENE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2021 | July 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17288966 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | April 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17288696 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROQUINONE DERIVATIVE FOR PREVENTING OR TREATING OBESITY OR NONALCOHOLIC STEATOHEPATITIS | April 2021 | June 2024 | Allow | 38 | 1 | 0 | No | No |
| 17288085 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17239137 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | April 2021 | March 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17222673 | METHODS OF REDUCING PLASMA LEVEL OF MACROPHAGE MIGRATORY INHIBITORY FACTOR IN PATIENTS | April 2021 | September 2024 | Allow | 42 | 2 | 1 | No | No |
| 17282632 | Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto | April 2021 | April 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17276605 | SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF | March 2021 | May 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17276763 | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST | March 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17276431 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | March 2021 | July 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17275209 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | March 2021 | April 2024 | Allow | 37 | 2 | 0 | No | No |
| 17275180 | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | March 2021 | September 2024 | Allow | 42 | 3 | 0 | No | No |
| 17196286 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | March 2021 | November 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17256969 | DRUG THAT REACTS WITH ACROLEIN, USE THEREOF AND NOVEL COMPOUND | March 2021 | June 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17271596 | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17270647 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | February 2021 | May 2024 | Allow | 39 | 1 | 0 | No | No |
| 17270767 | USES OF BALAENONE AND METHOD OF EXTRACTION THEREOF | February 2021 | April 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17270221 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | February 2021 | September 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17270236 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | February 2021 | October 2023 | Allow | 32 | 0 | 0 | No | No |
| 17268315 | AQUEOUS SUSPENSION-FORM PESTICIDAL COMPOSITION | February 2021 | April 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17268050 | TREATMENT OF RELAPSED FOLLICULAR LYMPHOMA | February 2021 | July 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17267636 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | February 2021 | May 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17267677 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | February 2021 | March 2024 | Allow | 37 | 1 | 0 | No | No |
| 17164817 | Inhibitors of Advanced Glycation End Products | February 2021 | July 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17263010 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | January 2021 | January 2025 | Allow | 47 | 2 | 0 | No | No |
| 17256837 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | December 2020 | February 2024 | Allow | 38 | 1 | 0 | No | No |
| 17112745 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | December 2020 | March 2025 | Allow | 51 | 1 | 1 | No | No |
| 17057983 | FUMARATE SALT OF 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[D]OXAZOL-2(3H)-ONE | November 2020 | May 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17029557 | Modulators of STING (Stimulator of Interferon Genes) | September 2020 | January 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 16756292 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | April 2020 | November 2024 | Abandon | 55 | 6 | 1 | Yes | No |
| 16618794 | COMBINATION OF IMMUNOTHERAPIES WITH MDM2 INHIBITORS | December 2019 | December 2022 | Abandon | 37 | 2 | 1 | No | No |
| 15774899 | ANTIMICROBIAL ADDITIVE | May 2018 | April 2025 | Allow | 60 | 9 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner PECKHAM, RICHARD GRANT works in Art Unit 1627 and has examined 84 patent applications in our dataset. With an allowance rate of 63.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner PECKHAM, RICHARD GRANT's allowance rate of 63.1% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PECKHAM, RICHARD GRANT receive 1.46 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PECKHAM, RICHARD GRANT is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.8% benefit to allowance rate for applications examined by PECKHAM, RICHARD GRANT. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.2% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.6% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.3% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.